Axa
VYGR icon

Axa’s Voyager Therapeutics VYGR Stock Holding History

Axa’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-99,000
Closed -$922K – 1138
2024
Q1 		$922K Hold
99,000
– – ﹤0.01% 854
2023
Q4 		$836K Hold
99,000
– – ﹤0.01% 873
2023
Q3 		$767K Buy
+99,000
New +$904K ﹤0.01% 874
2021
Q2 		– Sell
-174,500
Closed -$822K – 1309
2021
Q1 		$822K Sell
174,500
-15,200
-8% -$104K ﹤0.01% 1006
2020
Q4 		$1.36M Sell
189,700
-1,800
-0.9% -$17.3K ﹤0.01% 923
2020
Q3 		$2.04M Sell
191,500
-1,700
-0.9% -$20K 0.01% 809
2020
Q2 		$2.44M Buy
193,200
+181,700
+1,580% +$2.11M 0.01% 782
2020
Q1 		$105K Buy
11,500
+600
+6% +$6.89K ﹤0.01% 1138
2019
Q4 		$152K Buy
+10,900
New +$158K ﹤0.01% 1144
2018
Q3 		– Sell
-27,658
Closed -$540K – 1392
2018
Q2 		$540K Sell
27,658
-240,372
-90% -$4.75M ﹤0.01% 1118
2018
Q1 		$5.04M Sell
268,030
-68,777
-20% -$1.49M 0.02% 649
2017
Q4 		$5.59M Buy
+336,807
New +$5.77M 0.02% 618

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Axa's VYGR Position: Q2 2024 in Review

Axa sold out of Voyager Therapeutics (VYGR) in Q2 2024, closing a stake of 99,000 shares — an estimated $922K sold.

Axa first reported a position in VYGR in Q4 2017 and held it in 12 quarters. The position peaked at $5.59M in Q4 2017. 127 funds tracked by Wall St. Rank hold VYGR as of Q2 2024.

  • Axa reported no remaining Voyager Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Axa sold 99,000 Voyager Therapeutics shares in Q2 2024, an estimated $922K.
  • Axa first reported a position in Voyager Therapeutics in Q4 2017 and held it in 12 quarters.
  • Axa's Voyager Therapeutics position peaked at $5.59M in Q4 2017.
  • 127 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2024.

Based on Axa's 13F filing for Q2 2024, filed 14 Aug 2024.